论文部分内容阅读
目的:观察阿德福韦酯(ADV)联合苦参素治疗慢性乙型肝炎的临床疗效及安全性。方法:将100例确诊为慢性乙型肝炎的患者随机分为两组各50例,对照组50例使用ADV治疗,治疗组50例使用ADV联合苦参素治疗。结果:两组患者治疗6、12个月后的血清HBV DNA载量和ALT下降明显,与治疗前比较,差异有统计学意义(P<0.05);治疗12个月后,治疗组的血清HBV DNA载量和ALT明显低于对照组(P<0.05),血清HBV DNA的转阴率、ALT复常率、HBeAg转阴率和HBeAg血清学转换率明显高于对照组(P<0.05)。结论:ADV联合苦参素治疗慢性乙型肝炎临床疗效好,安全性高,值得临床推广应用。
Objective: To observe the clinical efficacy and safety of adefovir dipivoxil (ADV) combined with oxymatrine in the treatment of chronic hepatitis B. Methods: A total of 100 patients diagnosed with chronic hepatitis B were randomly divided into two groups of 50 cases. In the control group, 50 cases were treated with ADV and 50 cases were treated with ADV combined with oxymatrine. Results: Serum HBV DNA load and ALT decreased significantly after treatment for 6 and 12 months in both groups, with statistical significance (P <0.05). Before 12 months of treatment, serum HBV DNA load and ALT were significantly lower than those in the control group (P <0.05). Serum HBV DNA negative rate, ALT normal rate, HBeAg negative rate and HBeAg seroconversion rate were significantly higher than those in the control group (P <0.05). Conclusion: ADV combined with oxymatrine in the treatment of chronic hepatitis B has good clinical efficacy and high safety, which is worthy of clinical application.